Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition
-
Published:2024-04
Issue:
Volume:
Page:
-
ISSN:0022-202X
-
Container-title:Journal of Investigative Dermatology
-
language:en
-
Short-container-title:Journal of Investigative Dermatology
Author:
Adams RalphORCID,
Bunick Christopher G.ORCID,
Lawson Alastair D.G.ORCID,
Gomez BraulioORCID,
Shaw StevanORCID
Reference18 articles.
1. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F;Adams;Front Immunol,2020
2. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study;Blauvelt;J Am Acad of Dermatol,2020
3. The IL-17 family of cytokines in psoriasis: il-17A and beyond;Brembilla;Front Immunol,2018
4. The human IL-17A/F heterodimer: a two-faced cytokine with unique receptor recognition properties;Goepfert;Sci Rep,2017
5. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial [published correction appears in Lancet 2021;397:1182];Gordon;Lancet,2021